|
Dear Colleague:
We have come a long way since the early days of treatment for hepatitis C virus (HCV) infection, when dismal sustained viral response (SVR) rates and discontinuation of treatment due to severe side effects undermined the success we hoped our patients could achieve. Today, however, more than half of patients with HCV infection can achieve SVR and thus, a cure, thanks to strides in antiviral therapy and treatment management. Plan for Success: Effective Side Effect Management in Anti-HCV Therapy, a satellite symposium at this year’s DDW, focused on the very latest advances in HCV management, which may result in even more effective treatment offering greater promise to our patients. If you missed the symposium in New Orleans, you now have a second chance.
In Plan for Success: Effective Side Effect Management in Anti-HCV Therapy, renowned experts in hepatitis C discuss the latest strategies for optimizing treatment adherence and side effect management, with an eye toward reducing the medical necessity for dose reduction or treatment discontinuation and improving patient quality of life. We consider the latest data on treating hematologic side effects with adjuvant erythropoietin as well as approaches in treating neuropsychiatric side effects of antiviral therapy. We explore how to translate this data into practical clinical recommendations relevant to your own patients. Our discussion of case studies from patients we have treated illustrates how to optimize therapy in the patient infected with HCV and offers you examples for treating your own patients.
John G. McHutchison, MD, FRACP
Chair
top
Chair
John G. McHutchison, MD, FRACP
Director, Gastroenterology/Hepatology Research
Duke Clinical Research Institute
Associate Professor of Medicine
Duke University Medical Center
Durham, North Carolina
Faculty
Robert G. Gish, MD
Medical Director
Liver Transplant Program
California Pacific Medical Center
San Francisco, California
Mitchell L. Shiffman, MD
Chief, Hepatology Section
Medical Director, Liver Transplant Program
Virginia Commonwealth University Medical Center
Richmond, Virginia
Zobair M. Younossi, MD, MPH
Executive Director, Center for Liver Diseases
Medical Director, Liver Transplant Program
Inova Fairfax Hospital
Co-Director, Center for the Study of Genomics in Liver Diseases
Affiliate Professor of Biomedical Sciences
George Mason University
College of Arts and Sciences
Fairfax, Virginia
top
Agenda
State of the Science: Today’s Treatments for Hepatitis C
John G. McHutchison, MD, FRACP
Enhancing Sustained Virologic Response: Adherence Early During Therapy
Mitchell L. Shiffman, MD
Hematologic Side Effects and Growth Factors: Effects on Treatment Outcomes
Zobair M. Younossi, MD, MPH
Minimizing the Impact of Neuropsychiatric Effects During HCV Treatment
Robert G. Gish, MD
Case Studies and Q&A
Zobair M. Younossi, MD, MPH
Mitchell L. Shiffman, MD
Robert G. Gish, MD
Conclusion
John G. McHutchison, MD, FRACP
top
Target Audience
This activity has been designed for gastroenterologists and hepatologists who treat patients with hepatitis C.
Activity Goal
The goal of this professional education activity is to provide clinicians with up-to-date knowledge and practical clinical skills on optimizing response in HCV-infected patients by managing treatment side effects.
top
Learning Objectives
After participating in this activity, the physician should be able to:
- Evaluate the risk of developing depression and bone marrow suppression in their patients receiving anti-HCV therapy.
- Devise an appropriate testing and monitoring plan to diagnose depression and bone marrow suppression in patients on anti-HCV therapy.
- Incorporate current best practices in treating depression and bone marrow suppression in their patients on anti-HCV therapy.
- Enhance side effect management through an understanding of the relationship of adherence to early response rates.
top
CME Information
Statement of Accreditation
Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge designates this educational activity for a maximum of 1.5 Category 1 credits toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.
This activity is planned and implemented as an independent CME activity in accordance with the ACCME Essential Areas and Policies.
Successful completion for up to 1.5 hours of CME credit requires a passing score of 70% or higher on the posttest. Full instructions for submission are included on the posttest at the end of the webcast.
top
Disclosure Information
The Disclosure Policy of Projects In Knowledge requires that faculty participating in a CME activity disclose to the audience: any significant relationship they may have with a pharmaceutical or medical equipment company, product, or service that may be mentioned as part of their presentation; any relationship with the commercial supporter of this activity; if discussion includes 1) therapies that are unapproved for use or are investigational; 2) ongoing research; or 3) preliminary data. Faculty will disclose such discussion.
For complete prescribing information on the products discussed during this CME activity, please see your current Physicians’ Desk Reference (PDR).
Robert G. Gish, MD, has received grant/research support from, is a consultant for, and is on the speakers bureau of Amgen Inc, Bayer Corporation, Ortho Biotech Products, LP, Roche Pharmaceuticals, and Schering-Plough Corporation.
John G. McHutchison, MD, FRACP, has received grant/research support from Akros Pharma Inc, Amgen Inc, Bayer Pharmaceuticals Corporation, Biomedicines, Bristol-Myers Squibb Company, Cytel Corporation, Fujisawa Healthcare, Inc, GenProbe, Gilead Sciences, Inc, Idun Pharmaceuticals, Isis Pharmaceuticals, Inc, Ortho Diagnostic Systems, Inc, Prometheus Laboratories Inc, Ribozyme Pharmaceuticals, Inc, Roche Pharmaceuticals, Schering-Plough Corporation, SciClone Pharmaceuticals, Triangle Pharmaceuticals Inc, and Vertex Pharmaceuticals, Inc; is a consultant for Amgen Inc, Anadys Pharmaceuticals, Inc, Centocor, Inc, GlaxoSmithKline, InterMune Inc, Isis Pharmaceuticals, Inc, National Genetics Institute Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Prometheus Laboratories Inc, Ribozyme Pharmaceuticals, Inc, and Schering-Plough Corporation; and is on the speakers bureau of InterMune Inc, Roche Pharmaceuticals, and Schering-Plough Corporation.
Mitchell L. Shiffman, MD, has received grant/research support from Ortho Biotech Products, LP, Roche Pharmaceuticals, and Schering-Plough Corporation; is a consultant for Ortho Biotech Products, LP and Roche Pharmaceuticals; and is on the speakers bureau of Amgen Inc, Ortho Biotech Products, LP, Roche Pharmaceuticals, and Schering-Plough Corporation.
Zobair M. Younossi, MD, MPH, has received grant/research support from, and is a consultant for, Amgen Inc, InterMune Inc, Ortho Biotech Products, LP, Roche Pharmaceuticals, and Schering-Plough Corporation; and is on the speakers bureau of Amgen Inc, Ortho Biotech Products, LP, Roche Pharmaceuticals, and Schering-Plough Corporation. Dr. Younossi has disclosed that he will reference unlabeled/unapproved use of epoetin alfa and darbepoetin alfa.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the physician caring for the patient.
This independent CME activity is supported by an educational grant from
Amgen Inc.
top
top
 Recommend this to a colleague
|
